New Drug Developed Against Pancreatic Cancer Receives Approval from the US

The US Food and Drug Administration announced that it has granted official approval to a new drug stated to double the survival time of advanced-stage pancreatic cancer patients.

Approval Process and Characteristics of the Drug

This approval granted by the US Food and Drug Administration has opened a new door of hope in the fight against fatal pancreatic cancer.

The new drug, which is stated to double the survival time of advanced-stage pancreatic cancer patients, has received the necessary permission from health authorities.

Developing Company and Clinical Trials

The treatment method in question was developed by Revolution Medicines and tested in detail in large-scale clinical trials.

Following the comprehensive clinical trials conducted, the drug is planned to be launched under the name Rasonque.